Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1994-02-17
1995-10-10
Hollrah, Glennon H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
564308, 514567, 514614, A61K 31135
Patent
active
054571332
ABSTRACT:
R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
REFERENCES:
patent: 3201470 (1965-08-01), Huebner
patent: 3253037 (1966-05-01), Huebner
patent: 3513244 (1970-05-01), Gittos et al.
patent: 3513249 (1970-05-01), Gittos et al.
patent: 4826875 (1989-05-01), Chiesi
patent: 5196583 (1993-03-01), Yamada et al.
Finberg and Youdim, Modification of blood pressure and nictitating membrane response to symphathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat, British J. Pharmac. (Jun. 1985) 85(2):541-546 (Exhibit E).
Kabins and Gershon, Potential applications for monoamine oxidase B inhibitors Dementia (1990) 1:323-348 (Exhibit F).
The Merck Index (Tenth ed. 1983) pp. 149, 248-249 (Exhibit G).
The Parkinson Study Group, Effect of deprenyl on the progression of disability in early Parkinson's disease, New England J. Med. (1989) 321(20):1364-1371 (Exhibit H).
The Parkinson Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease, New England J. Med. (Jan. 21, 1993) 328(3):176-183 (Exhibit I).
Riederer and Youdim, Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with 1-deprenyl, J. Neurochem. (1986) 46(5):1359-1365 (Exhibit J).
Tekes, et al., Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain, Pol. J. Pharmacol. Pharm. (1988) 40:653-658 (Exhibit K).
Youdim et al. in Handbook of Experimental Pharmacology vol. 90/I (1988) Chapter 3, Trendelenburg and Weiner, eds. (Exhibit L).
Finberg et al., Brit. Journal of Pharmac. (1985) 85:651-6.
The Merck Index, Tenth Ed. (1983) pp. 149, 248-9.
Berger-Paskin Tirtsah
Finberg John P. M.
Lerner David
Levy Ruth
Sterling Jeffrey
Burn Brian M.
Hollrah Glennon H.
Technion Research and Development Foundation Ltd.
Teva Pharmaceutical Industries Ltd.
White John P.
LandOfFree
R-enantiomers of N-propargyl-aminoindan compounds, their prepara does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with R-enantiomers of N-propargyl-aminoindan compounds, their prepara, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and R-enantiomers of N-propargyl-aminoindan compounds, their prepara will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2310702